VTGN - VistaGen Therapeutics Inc

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.

52W High

$3.88

52W Low

$1.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.55

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.19

EV/Revenue (<3 favorable)

74.45

P/S (TTM) (<3 favorable)

168.60

P/B (<3 favorable)

1.92

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.34%

Institutions (25–75% balanced)

50.15%

Shares Outstanding

30,680,500

Float

21,935,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

646,000

Gross Profit (TTM)

646,000

EPS (TTM)

-1.79

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-64.77%

ROE (TTM) (>15% strong)

-0.69%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.91

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—